Oxigene Inc fka OXGN

[Millonario]

$OXGN read facts > GLTA Bullish

Freitag, 14. März 2014

$OXGN Potential Buyout Target flying under radar !!!

Oxigene Positive Ovarian Cancer Study Success ZYBRESTAT Topical, a reformulation aimed at ophthalmological disorders has the potential to address a market of $360 billion in age related macular degeneration (AMD) and Polypoidal Choroidal Vasculopathy (PCV)

Roche's Avastin is not approved for ovarian cancer in the U.S.
Zybrestat could still be extremely helpful to Avastin in gaining FDA approval

OXGN have a first class VDA Platform and it is still under Investors radar

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancers, such as ovarian and certain thyroid cancers.

The Company’s major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumors.

OXiGENE is dedicated to leveraging its scientific expertise, intellectual property and therapeutic development capabilities to bring life-extending and life-enhancing medicines to patients.

About VDAs Vascular Disrupting Agents or “VDAs” block blood flow through established tumor blood vessels, thereby starving tumors of oxygen and essential nutrients, leading to tumor cell death.

The phase II study, conducted by the non-profit Gynecologic Oncology Group, not Oxigene, enrolled 107 women with platinum-sensitive and resistant, recurrent ovarian cancer. The patients were randomized to receive either Roche's Avastin alone, or a combination of Zybrestat and Avastin. On the study's primary endpoint, the combination of Zybrestat and Avastin reduced the risk of tumor regrowth or death (progression-free survival) by 32% compared to Avastin alone. The result was very statistically significant

Some facts about Oxigene 15.2 Million Shares = 60,8 Million Market CAP and $25 million Cash !

OXiGENE’s Development Pipeline is comparable with Celldex pipeline Here's some information taken directly from the OxiGENE BIO CEO Conference presentation.

Current chemotherapy is notorious for killing healthy cells along with cancerous ones
– The Zybrestat/Avastin combination is designed to change that.

Zybrestat kills tumor cells by selectively blocking the blood vessels
that carry vital oxygen and nutrients to tumors.

Let's keep it simple and give you these Fact Results:

v One-year survival rate 25.5% vs. 8.7%
v Median Overall Survival 5.2 vs. 4.0 months (HR 0.72)
v 25% higher Objective Response rate (20% vs. 16%)
v VDAs reduced blood flow to the center of the tumors by 70%

Abstract VDAs - Oxgn leading the way..

The tumor vasculature of solid tumors offers unique characteristics compared to the normal vasculature and, therefore, represents an attractive target in anti-cancer therapy.

Besides the classic anti-angiogenic agents, which inhibit tumor neovascularization, a novel promising class of anti-tumor drugs has emerged in the last years, the vascular-disrupting agents (VDAs). In contrast to angiogenesis inhibitors, VDAs act on already established tumor blood vessels of large solid tumors and induce a vascular shutdown by targeting tumor endothelial cells. This results in extensive necrotic tumor cell death.

The sources of VDAs are quite divers, however, the plant-derived compounds represent the largest and most prominent class. Plant-derived VDAs have undergone extensive preclinical investigations and are now tested in several advanced clinical trials. In this review we summarize preclinical data, including drug-target relationships as well as functional in vitro and in vivo assays, discuss their molecular way of action, and update the clinical status of the most prominent plant-derived VDAs: FAA/DMXAA, CA-4-P, OXi4503, AVE8062, and ZD6126.

All these data emphasize the value of secondary plant metabolites and their (semi-)synthetic derivatives for current drug discovery.

More information please visit OXIGENE H.P :
Pipeline http://www.oxigene.com/product-development


http://bioinvestor204.blogspot.de



LOBO